Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is positioned to capitalize on the growing demand for medical devices in the aging population and advancements in technology for orthopedic procedures, making it a strong long-term investment with potential for further expansion into emerging markets.

Bears say

Enovis is facing some fundamental challenges that could impact its stock value negatively in the future. These include the company's high reliance on its Prevention & Recovery segment for revenue, which may limit its growth potential in the long term. Additionally, the highly fragmented and competitive markets in which Enovis operates, with larger companies having greater resources and scale, could pose significant obstacles for Enovis to overcome. Furthermore, Enovis is exposed to risks such as potential disruptions to operations due to the integration of recent acquisitions, and the impact of tariff increases on its supply chain. These factors could potentially lead to lower margins and slower revenue growth, which may impact investor confidence and result in a negative outlook for Enovis's stock.

Enovis Corp (ENOV) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.